Chapter 150 Annual Report Profit Inventory (please subscribe)
"Dr. Muller, Dr. Marcus, I'm going to trouble you next. We need to use this drug patent to re-develop an injectable catalyst. ', I guess this request is not too difficult for you."
"Okay, Mr. Zhang, this request is indeed not too difficult;
There is no limit on the dissolution time. If it is injected directly into the human body, many problems can be solved. However, animal experiments and drug toxicity tests need to be done again, which may take a long time. ”
Qingshan Pharmaceutical Drug Research and Development Center, the person who answered Zhang Yang was Dr. Muller, the former person in charge of the "BI-Toxin Catalyst" project.
The purpose of the two of them coming to Tsingshan Pharmaceutical was naturally to help the members of the R&D team of Tsingshan Pharmaceutical better understand the patent composition and efficacy mechanism of the "catalyst", so as to develop new drugs.
So Zhang Yang’s request is reasonable.
"By the way, President Zhang, I have always heard that your company also has a drug research and development project of 'macromolecular toxin catalyst'. Can I know about your project?"
"Don't worry. , your research and development results must have been patented, and I will not be shameless enough to steal your results. I just want to learn more with a learning attitude."
Zhang Yang's expression suddenly became a little strange, where is he? Any "macromolecule toxin catalysts" are nothing more than smoke bombs.
Zhang Yang's weird expression surprised the old-fashioned Germans, and gradually Dr. Mueller also came to his senses.
His eyes suddenly widened:
"Zhang, you won't tell me that you never had this project from the beginning to the end, right?"
Zhang Yang shrugged. :
"Dr. Mueller, listen to me, we have indeed established this project, but the progress is a little slow..."
Zhang Yang explained to Mueller slightly awkwardly.
After all, Dr. Muller will stay at Qingshan Pharmaceutical for a year to help them understand the patent of "BI Toxin Catalyst", so he will definitely know the truth after long-term contact.
Instead of In this case, it is better to be honest.
Of course, he doesn't care much about BI knowing the truth.
This is originally a matter of business negotiation. Since negotiation, everyone should rely on their ability. Besides, the price of 1.45 billion is too much to owe BI Company.
After taking Mueller and Dr. Marcus to eat delicious food in the gourmet capital of Chengdu for three consecutive days, Dr. Mueller had put all his dissatisfaction behind him.
With the personal guidance of two former project leaders of BI Company, the research and development of Tsingshan Pharmaceutical’s injection “catalyst” project has made rapid progress.
Zhang Yang’s plan is to first use the patented “BI Toxin Catalyst” to develop a “macromolecule catalyst” for injection, and then form an AB bottle of combined medicine with “Shenduqing”.
After completing this work, we will consider fusing the effective decomposition components in the "catalyst" and adding them to "Kidney Toxin" so that "Kidney Toxin" can decompose both small molecule toxins and Macromolecule toxins, thereby achieving the effect of increasing the toxin clearance rate.
Of course, this is all in the future.
After arranging the direction of the next improvement of "Kendu Qing", Zhang Yang also knew that the "Kendu Qing" matter was over. Next, he would wait for the "Macromolecule Toxin Catalyst" for injection to be launched, and then serve more people. Dialysis patients.
After returning to the office from the drug research and development center, Zhang Yang finally breathed a sigh of relief when he was alone.
He picked up the tea cup and took a sip, then walked slowly to the window, and his eyes suddenly fell on the security room not far away.
He thought of Jiang Yong.
He still remembered what Jiang Yong said to him that day in the hospital:
"Mr. Zhang, I also want to raise two children with my own hands, rather than relying on your mercy."
Suddenly, he felt relaxed and happy for no reason.
After getting "Shenduqing", Jiang Yong should be able to find a job he likes, and he should be able to raise two children with his own hands, right?
Except for Jiang Yong, those young dialysis patients should all have a better life.
Gradually, he thought of those patients with "stage three kidney disease" and "stage four kidney disease". Now the hospital has fully begun to promote the trial of "Shenduqing" in stage three kidney disease...< br>
If it is truly universal and has the effect of delaying or preventing the progression of the disease, those patients suffering from "chronic kidney disease" should also be able to see their own light of hope in the midst of pessimism, right?
Being sick is not scary. What is scary is not seeing hope.
Fortunately, there is hope now.
Zhang Yang exhaled gently.
Finally, he thought of the "toxin catalyst" for the acquisition of BI Company.
To be honest, it's just luck.
He never expected that "Shenduqing" would have such a big impact on the hemodialysis consumables market. He did not expect that Chengdu Third People's Hospital could publish the results of "Shenduqing" on "Kidney Stage III and IV" academic papers, which completely cut off the future prospects of the blood consumables market.
If this were not the case, BI Company would not give up "BI-Catalyst" so easily, and I probably would not be able to get such a bargain.
However, regardless of luck or strength, if "BI-Catalyst" falls into his own hands, he will always be able to better treat more kidney disease patients.
After thinking about it, Zhang Yang’s thoughts finally landed on the amount of this negotiation.
To be honest,
He had not paid much attention to Qingshan Pharmaceutical's annual profits before. He originally thought that the cash flow of more than 20 billion was enough.
But when it came time to actually carry out large-scale BD transactions, I discovered that the funds I had always thought were a lot of money only amounted to a few hundred million US dollars.
Three billion dollars is already an astronomical figure in other industries, but it is nothing in the pharmaceutical industry. In the past few days, he specifically inquired about some of the largest BD transactions in the world last year, among which Pfizer of the United States spent US$43 billion to acquire four oncology drugs from Seagen...
Not to mention Pfizer, even the domestic Hengrui Pharmaceuticals. Among the transactions with Merck of Germany last year, one of the BD transactions exceeded US$4 billion.
Look again at the profits of the world's top ten pharmaceutical companies last year.
Johnson & Johnson of the United States had revenue of US$85.16 billion and net profit of US$35.1 billion last year.
Pfizer of the United States has annual revenue of US$58.5 billion and net profit of US$31.6 billion.
The top ten or even top twenty pharmaceutical companies such as Roche, Novartis, Merck, AbbVie, etc. all have revenue exceeding US$15 billion.
After calculation, Johnson & Johnson can earn 250 billion yuan a year.
“Tsingshan Pharmaceutical may already be a first-tier pharmaceutical company in China, but there is still a big gap compared with foreign pharmaceutical companies.”
“At least, in terms of earning power, there is a big gap. Big!”
“There is still a long way to go, we still need to improve our profitability!”
Zhang Yang said silently.
Immediately, he called the financial director Lao Qian again.
This time he didn't want to ask how much money was currently in the account, but wanted to take a closer look at the profit sources of the company's entire drug product line last year.
Lao Qian quickly came to Zhang Yang's office with detailed financial report data.
As we all know, Qingshan Pharmaceutical currently has a total of five drugs and one health product for external sales.
The first product is "Avatrombopag Qingshan".
After "Qingshan Ava" has been fully promoted in medicine in recent years, the annual sales volume has reached 3.5 million boxes, occupying 62% of the market share in the entire "thrombocytopenia" drug field.
The annual sales amount was 1.68 billion and the net profit was 1.35 billion.
Zhang Yang has great affection for "Qingshan Afa". After all, this is the first drug launched by Qingshan Pharmaceutical.
But he also knows that because Qingshan Ava has joined the "Grain Miao Plan", the medical insurance purchase price is 480 yuan a bottle, and there are only so many patients with blood diseases in the country,
it can occupy 62% of the market. , it would be good to make a stable profit of 1.35 billion a year.
Then, he looked at "ITG human genitin".
ITG Human Genetin can completely cure aplastic anemia and costs 2,800 yuan per injection. In the past two years, after the first batch of patients with aplastic anemia were cured, the sales volume obviously began to decrease last year.
But this is also expected.
The latest statistics show that the number of domestic patients with aplastic anemia has dropped from 1.5 million to 720,000, and the vast majority of them are patients with common aplastic anemia.
They were forced by economic pressure, or they didn't pay attention to it, so they took medicine to maintain it, which also caused ITG's sales to begin to decline.
Last year, a total of 800,000 tubes were sold, with ten tubes per person. In total, 80,000 aplastic patients were cured throughout the year.
Sales amount reached 2.24 billion yuan, with net profit of 1.76 billion yuan.
“ITG myelopoietin” is sold to Southeast Asia and the United Kingdom, and the situation in these two regions is similar to that in China.
As the first batch of patients who are most eager to be cured have been cured, sales have dropped significantly in the past two years.
Only 60,000 bottles of "ITG myelopoietin" were sold in Southeast Asia throughout the year, and only 6,000 people received treatment in Southeast Asia.
The sales amount was US$180 million and the net profit was US$174 million, which is converted into RMB 1.2 billion.
Only 10,000 people in the UK received treatment, with a profit of 2.2 billion yuan.
In total, ITG human myelopoietin has contributed 5.16 billion to Tsingshan Pharmaceuticals globally.
“The next one is ‘Acofenprovir’.”
When he saw the purchase quantity last year, Zhang Yang felt a little sad but also a little happy.
"Ixaprofen", which cures hepatitis B, was purchased with special funds from the National Medical Insurance Administration and will be provided to hepatitis B patients free of charge after purchase.
The first batch purchased 10 million bottles, and the second batch purchased 20 million bottles.
As nearly 60 million bottles were purchased in the next few years, the purchase volume of the Medical Insurance Bureau began to decrease.
This means that at least 30 million hepatitis B patients have been cured, and the remaining ones who have not received free medicine are either due to lack of information, purchasing it through pharmacies themselves, or other reasons.
The bad news is that last year, the purchase quantity of the Medical Insurance Bureau dropped to 10 million bottles, the sales amount was only 5 billion, and the profit was only 4 billion.
Moreover, like "ITG Generator", the profits of "Icofenprofovir" to cure hepatitis B will be close to zero before long.
Seeing that it was almost difficult for the first three drugs to create a lot of profits, Zhang Yang suddenly felt a little mixed.
Chapter owed -1, there is only one chapter left, I will finish it tomorrow!
(End of this chapter)